InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Entera Bio is a clinical-stage biopharmaceutical company focused on the developmen...
Entera Bio is a clinical-stage biopharmaceutica...
Harvard Bioscience is a global developer, manufacturer and marketer of a broad ran...
Harvard Bioscience is a global developer, manuf...
Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai...
Cellect Biotechnology Ltd. was founded in 2011 ...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company...
VistaGen Therapeutics (NASDAQ: VTGN) is a clini...
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel pr...
Novavax, Inc. is a clinical-stage vaccine compa...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.